Akso Health Group Sponsored ADR (AHG) AI Stock Analysis

• Market Cap: $899.53M
• Dividend Yield: N/A
• Average Volume (3M): 27.06K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.26
• Revenue Growth: 510.69%
• EPS Growth: -145.92%
• Country: US
• Employees: 9
• Sector: Healthcare
• Sector Strength: 51
• Industry: Financial - Credit Services
• EPS (TTM): -0.06
• Shares Outstanding: 549,200,900
• 10 Day Avg. Volume: 8,269
• 30 Day Avg. Volume: 27,057
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 45 Neutral
• Price Target: ―

The overall stock score for Akso Health Group is low due to significant challenges in profitability and revenue stability. The technical analysis points to negative momentum, while the valuation is weak with a negative P/E ratio. The recent market reaction post-earnings call was negative, further impacting the score. Without positive corporate events or earnings call highlights, the outlook remains cautious.

Akso Health Group Sponsored ADR Business Overview & Revenue Model

Company Description

Akso Health Group Sponsored ADR (AHG) is a healthcare company focused on providing comprehensive health services primarily in the fields of traditional Chinese medicine and integrated healthcare solutions. The company operates in various sectors including healthcare services, wellness management, and health-related technology, aiming to enhance patient care and promote overall well-being through innovative practices and treatments.

How the Company Makes Money

Akso Health Group generates revenue through a diversified model that includes providing healthcare services such as traditional Chinese medicine consultations, wellness management programs, and integrated healthcare solutions. The company collaborates with healthcare institutions and leverages its expertise in both traditional and modern medical practices to offer a wide range of services. Revenue streams are primarily driven by patient consultations, treatment programs, and strategic partnerships with healthcare providers and technology firms that enhance its service offerings. Key factors contributing to its earnings include the growing demand for alternative medicine, expansion into new markets, and the integration of technology in healthcare services to improve efficiency and patient outcomes.

Akso Health Group Sponsored ADR Financial Statement Overview

Summary

Akso Health Group faces challenges with profitability and revenue stability. While its balance sheet shows a strong equity position, the lack of comprehensive debt information introduces uncertainty in financial leverage assessment. Cash flow has improved recently, but historical volatility poses a risk. Overall, the company needs to address its revenue and profitability issues to enhance financial health.

Income Statement

The company has experienced significant revenue volatility, with a steep decline in recent years. The net profit margin is severely negative due to substantial net losses, indicating poor profitability. There is no gross profit data to assess cost efficiency, and EBIT/EBITDA margins are unavailable for additional insights.

Balance Sheet

The equity ratio is strong, indicating a solid equity base relative to total assets. However, the lack of debt data prevents a full assessment of leverage. Stockholders' equity has increased recently, but the company has a history of equity fluctuations.

Cash Flow

The company has shown inconsistent operating cash flows, with recent positive figures. Free cash flow has been volatile, with significant growth over the past year, albeit from a low base. The cash flow to net income ratio is unreliable due to negative net income.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.41M	14.78M	2.41M	13.18M	6.00M	1.75M
Gross Profit	122.13K	-281.53K	122.13K	1.27M	605.13K	1.21M
EBITDA	0.00	-1.77M	0.00	-14.25M	-2.44M	-2.07M
Net Income	-9.06M	-134.98M	-9.46M	-13.08M	-16.85M	-31.55M
Balance Sheet
Total Assets	142.02M	214.95M	142.02M	20.46M	50.68M	31.69M
Cash, Cash Equivalents and Short-Term Investments	85.17M	176.23M	85.17M	7.92M	21.93M	15.13M
Total Debt	2.00M	81.74K	2.00M	9.69M	37.20M	10.00M
Total Liabilities	3.59M	15.80M	3.59M	11.62M	38.39M	14.41M
Stockholders Equity	138.37M	199.12M	138.37M	8.73M	12.28M	17.27M
Cash Flow
Free Cash Flow	1.35M	1.02M	1.35M	-3.25M	-8.63M	10.06M
Operating Cash Flow	1.35M	1.18M	1.35M	-3.25M	-8.63M	10.06M
Investing Cash Flow	-54.72M	-105.91M	-54.72M	18.47M	-19.96M	-662.00
Financing Cash Flow	131.65M	195.88M	131.65M	-27.51M	34.78M	-9.04M

Akso Health Group Sponsored ADR Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.73
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AHG, the sentiment is Neutral. The current price of 1.73 is below the 20-day moving average (MA) of 1.75, above the 50-day MA of 1.66, and above the 200-day MA of 1.37, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 42.10 is Neutral, neither overbought nor oversold. The STOCH value of 19.50 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AHG.

Akso Health Group Sponsored ADR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MFIN	81 Outperform	$250.83M	5.94	11.25%	4.20%	15.88%	-1.83%
YRD	76 Outperform	$500.29M	2.87	13.64%	6.81%	12.69%	-35.36%
QD	70 Outperform	$741.42M	10.61	4.57%	―	-39.25%	―
FOA	64 Neutral	$675.50M	30.12	33.40%	―	276.86%	―
OPRT	56 Neutral	$297.06M	―	-1.26%	―	-5.87%	94.07%
Sector *	51 Neutral	$7.92B	-0.43	-41.69%	2.21%	22.29%	-1.85%
AHG	45 Neutral	$899.53M	―	-79.90%	―	510.69%	-145.92%